Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intensive Chemotherapy and PBSC Transplant in CML and High-Risk Acute Leukemia
NCT00004905Phase 2Completed
- Sponsor
- Loyola University Chicago
- Start
- Oct 1999
- Modality
- Cytokines & Interferons, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cytarabine, etoposide, idarubicin, cyclophosphamide, filgrastim and 1 more in chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), sponsored by Loyola University Chicago. Primary endpoint: Safety and Toxicity of Induction and Transplant Regimens. Started Oct 1999; status: completed.
02
Drugs
cytarabineetoposideidarubicincyclophosphamidefilgrastim
03
Conditions
chronic myeloid leukemia (CML)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00004905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004905.